TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...
The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback